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Abstract
Previous studies have reported that mesenchymal stem cells
(MSC) may be isolated from the synovial membrane by the same
protocol as that used for synovial fibroblast cultivation,
suggesting that MSC correspond to a subset of the adherent
cell population, as MSC from the stromal compartment of the
bone marrow (BM). The aims of the present study were, first, to
better characterize the MSC derived from the synovial
membrane and, second, to compare systematically, in parallel,
the MSC-containing cell populations isolated from BM and
those derived from the synovium, using quantitative assays.
Fluorescent-activated cell sorting analysis revealed that both
populations were negative for CD14, CD34 and CD45
expression and that both displayed equal levels of CD44, CD73,
CD90 and CD105, a phenotype currently known to be
characteristic of BM-MSC. Comparable with BM-MSC, such
MSC-like cells isolated from the synovial membrane were shown
for the first time to suppress the T-cell response in a mixed
lymphocyte reaction, and to express the enzyme indoleamine
2,3-dioxygenase activity to the same extent as BM-MSC, which
is a possible mediator of this suppressive activity. Using
quantitative RT-PCR these data show that MSC-like cells from
the synovium and BM may be induced to chondrogenic
differentiation and, to a lesser extent, to osteogenic
differentiation, but the osteogenic capacities of the synovium-
derived MSC were significantly reduced based on the
expression of the markers tested (collagen type II and aggrecan
or alkaline phosphatase and osteocalcin, respectively).
Transcription profiles, determined with the Atlas Human
Cytokine/Receptor Array, revealed discrimination between the
MSC-like cells from the synovial membrane and the BM-MSC by
46 of 268 genes. In particular, activin A was shown to be one
major upregulated factor, highly secreted by BM-MSC. Whether
this reflects a different cellular phenotype, a different amount of
MSC in the synovium-derived population compared with BM-
MSC adherent cell populations or the impact of a different
microenvironment remains to be determined. In conclusion,
although the BM-derived and synovium-derived MSC shared
similar phenotypic and functional properties, both their
differentiation capacities and transcriptional profiles permit one
to discriminate the cell populations according to their tissue
origin.
Introduction
Mesenchymal stem cells (MSC) are progenitor cells that have
the potential to differentiate into lineages of mesenchymal tis-
sues including cartilage, bone, muscle and fat. They were ini-
tially isolated from bone marrow (BM) and characterized by the
expression of various cell surface markers [1,2]. MSC have
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more recently been obtained from adipose tissue, peripheral
blood, cord blood, cartilage [3-6] and synovial tissue [7].
Identification of MSC in the synovium has raised speculations
about their biological role in the normal or pathologic joint
physiology. As MSC have a great potential to repair damaged
tissues, they are likely to contribute to joint regeneration in
arthritis. Indeed, MSC have been detected in the synovial fluid
of patients with arthritis, with a higher prevalence in osteoar-
thritis (OA). In this OA, MSC may participate in the highly
active process of regeneration due to the reactivation of endo-
chondrial ossification in the advanced phase of the disease
[8]. However, a significant reduction in the in vitro chondro-
genic and adipogenic activities of MSC has been reported in
patients with OA [9]. The authors suggest that changes in the
differentiation profile of MSC account for the increase of bone
density and loss of cartilage that are characteristics of OA.
Recent data suggest a possible involvement of MSC in the
pathophysiology of OA, but also in inflammatory arthritis [10].
In the study, the authors show that during the induction phase
of collagen-induced arthritis, marrow-derived mesenchymal
cells accumulate in the synovium preceding the clinical onset
of arthritis and afflux of inflammatory cells [10]. Thus, although
still to be demonstrated, MSC may play a pivotal role in the
induction phase of arthritis by promoting the accumulation of
immunocompetent cells into the joint.
To date, identification of MSC from the synovial membrane
exclusively relies on their phenotypic characterization and on
the assessment of their differentiation potential. MSC from the
synovial membrane were shown to express various surface
markers (CD9, CD10, CD13, CD44, CD54, CD55, CD90,
CD105, CD166, D7-FIB) and to be negative for CD14, CD20,
CD45 and CD133 by fluorescent-activated cell sorting
(FACS) analysis [7,8,11]. A more detailed study involving
molecular characterization of MSC from the synovial mem-
brane by RT-PCR has revealed the expression of various
matrix molecules, adhesion molecules, ligands, receptors and
transcription factors [7]. Functional characterization of MSC
from the synovial membrane has shown their multilineage
potential as they are able to differentiate towards chondro-
cytes, osteoblasts, adipocytes and, to a lesser extent, towards
myocytes [7].
Isolation of MSC from the synovium [7,11], mainly based on
adhesion properties, relies on the technique used to isolate
synovial fibroblasts, suggesting that only a subset of the cell
population corresponds to the MSC. On the basis of the
present knowledge of the biology of BM-derived MSC, we
underwent parallel studies to phenotypically and functionally
compare the MSC isolated from both tissues. Interestingly,
using quantitative analyses, our results show that the potential
of differentiation towards osteocytes were significantly
reduced in synovium-derived MSC. The present study is the
first to demonstrate that MSC from the synovial membrane
share the same immunosuppressive features as BM-MSC
because they are able to inhibit the T-cell proliferation in a
mixed lymphocyte reaction (MLR) and to display indoleamine
2,3-dioxygenase (IDO) activity. Importantly, using macroarray
technology we provide evidence that the transcriptional pro-
files could be used to discriminate the MSC by function of
their tissue origin, Activin A being one major upregulated gene
in BM-MSC.
Materials and methods
Cell culture
Human MSC cultures were established from BM aspirates of
healthy donors or from OA patients and rheumatoid arthritis
(RA) patients undergoing hip replacement surgery, after
informed consent. The cell suspension was diluted in serum-
free medium, filtered on a nylon membrane (Cell Strainer; Dut-
scher, Cergy, France) and centrifuged at 200 × g for 10 min
at ambient temperature. Mononuclear cells were then plated at
the density of 5 × 104 cells/cm2 in α-MEM, supplemented with
10% fetal bovine serum (Perbio Science France SAS,
Brebières, France), 1 ng/ml basic fibroblast growth factor, 100
U/ml penicillin and 100 µg/ml streptomycin. When cultures
reached near confluence, cells were detached with 0.05%
trypsin and 0.53 mM ethylenediamine tetracetic acid, and
were subsequently replated at the density of 1,000 cells/cm2.
BM adherent cells were used between passage 2, when a
homogeneous population of cells was microscopically
observed, and passage 7. The median age of the BM-MSC
samples was 53.13 ± 18.3 years, corresponding one-half to
healthy donors and approximately one-quarter to RA patients
and one-quarter to OA patients.
Human synovium-derived adherent cells were isolated from
synovial tissues either post mortem (healthy donors) or at the
time of surgical knee replacement for degenerative OA or RA.
Synovial tissues were finely minced and digested with 0.2%
collagenase in DMEM containing 10% fetal bovine serum, 100
U/ml penicillin and 100 µg/ml streptomycin (complete
DMEM). Following overnight incubation at 37°C, cells were
collected by centrifugation, washed once and filtered on a
nylon membrane (Cell Strainer; Dutscher). The cell suspen-
sion was then plated in complete DMEM in a 75 cm2 flask and
passaged when reaching near confluence according to previ-
ous report [7]. Synovial cells were used between passage 4
and passage 8. The median age of synovium-derived MSC
samples was 54.6 ± 28.8 years, corresponding one-half to RA
patients and approximately one-quarter to OA patients and
one-quarter to healthy donors. Due to ethical considerations,
BM-derived and synovium-derived cells were not obtained
from the same patients.
Phenotypic characterization
For flow cytometry, cells were harvested by treatment with
0.05% trypsin and 0.53 mM ethylenediamine tetracetic acid,
and were resuspended in PBS containing 0.1% BSA andAvailable online http://arthritis-research.com/content/7/6/R1304
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0.01% sodium azide. Cell aliquots (105 to 5 × 105 cells/100
µl) were incubated on ice with conjugated mAbs against
CD14, CD34, CD44, CD45, CD73, CD90 and CD105 (BD
Pharmingen, Le Pont de Claix, France) or conjugated isotypic
controls. Flow cytometry was performed on a fluorescence-
activated cell sorter (FACS Scan, BD Biosciences, Le Pont de
Claix, France), and data were analyzed with the Cellquest soft-
ware (BD Pharmingen).
For immunofluorescence analysis, cells were fixed with ace-
tone:methanol (1:1), washed with PBS and incubated with the
primary mAb specific for the human prolyl-4-hydroxylase
(Dako, Trappes, France) at 1:50 dilution for 30 min at room
temperature. Washed slides were then incubated with a sec-
ondary fluorescein isothiocyanate-conjugated goat anti-mouse
antibody for 30 min in the dark. Fluorescence was visualized
using a Zeiss standard microscope equipped with an Axio-
Cam MRcamera (Carl Zeiss Vision, Le Pecq, France).
Induction of genes by interferons
Cells were cultured in the presence of 1,000 U/ml IFN-α, IFN-
β or IFN-γ at 37°C for 6 or 48 hours in the case of IFN-γ.
Expression of major histocompatibility complex (MHC) class I
and class II molecules was detected by flow cytometry using
mAbs specific for HLA-A, HLA-B, HLA-C and anti-HLA-DR
molecules (W6.32 and L243 clones, respectively). Induction
of the 6–16 gene rapidly induced by IFNs was recorded by
quantitative real-time PCR as previously described [12].
Chondrogenic differentiation and osteogenic 
differentiation
Chondrogenic differentiation was induced by a 21-day culture
in micropellet. Briefly, cells (2.5 × 105 cells) were pelleted by
centrifugation in 15 ml conic tubes and cultured in BMP-2-
conditioned chondrogenic medium. Osteogenesis was
induced by culture at low density (1.5 × 104 cells in a 100-mm-
diameter culture dish) for 21 days in BMP-2-conditioned oste-
ogenic medium. The conditioned media were obtained after
incubation of C9 cells at confluence for 48 hours in the pres-
ence of either chondrogenic medium or osteogenic medium.
C9 cells are derived from the C3H10T1/2 murine MSC line,
and they express 1,230 ng hBMP-2 per 24 hour/106 cells
under the control of a TetOff promoter [13]. As the control,
supernatants from C3H10T1/2 cells were unable to induce
any cell differentiation (data not shown). The chondrogenic
medium consisted of DMEM supplemented with 0.1 µM dex-
amethasone (Sigma, l'Isle d'Abeau, France), 0.17 mM ascor-
bic acid and 1% insulin-transferrin-sodium selenite media
supplement (Sigma). The osteogenic medium consisted of
DMEM medium supplemented with 10% FCS, 10 mM β-glyc-
erophosphate (Sigma), 0.1 µM dexamethasone (Sigma) and
0.05 mM ascorbic acid (Sigma). The adipogenic differentia-
tion potential for BM-derived and synovium-derived MSC has
been checked according to a previously described protocol
[14].
Real-time RT-PCR
Total RNA was extracted from cell micropellets using the RNe-
asy mini kit (Qiagen S.A., Courtaboeuf, France) and from cells
in monolayers using the Promega SV Total RNA Isolation Sys-
tem protocol (Promega, Charbonnières-les-bains, France) as
recommended by the suppliers. Total RNA was reverse tran-
scribed using Multiscribe reverse transcriptase (Applied Bio-
systems, Courtaboeuf, France). The TaqMan gene expression
arrays and the TaqMan Universal Master Mix were used
according to the manufacturer's recommendations (Applied
Biosystems). Measurement and analysis of gene expression
were performed using the ABI Prism 7000 Sequence Detec-
tion System software (Applied Biosystems). Content of cDNA
samples was normalized by subtracting the number of copies
of the endogenous GAPDH reference gene from the number
of copies of the target gene (∆Ct = Ct of target gene – Ct of
GAPDH). Expression of the specific gene was calculated
using the formula 2-(∆Ct).
Mixed lymphocyte reaction
MLRs were performed as previously described [15]. Briefly,
splenocytes from BALB/c mice and DBA/1 mice were isolated
and stimulator splenocytes were inhibited to proliferate by
treatment with 50 µg/ml mitomycin C (Sigma) at 37°C for 45
min. Each responder cell population and each stimulator cell
population was seeded in triplicate at the concentration of 105
cells/100 µl per well, in 96-well round-bottom plates (BD Bio-
sciences, Le Pont de Claix, France). Synovium-derived and
BM-derived adherent cells (105 cells) were added to the MLR
to obtain a 300 µl final volume. After 3 days of incubation, 1
µCi/well [3H]thymidine was added overnight and thymidine
incorporation was measured using a β-scintillation counter.
Each experiment was performed at least three times.
IDO activity measurement
Cells were stimulated with IFN-γ (1,000 U/ml) and/or tumor
necrosis factor alpha (TNF-α) (50 ng/ml) for 48 hours in
DMEM supplemented with L-tryptophan (100 µg/ml). IDO
enzyme activity was measured by tryptophan-to-kynurenine
conversion with photometric determination of the kynurenine
concentration in the supernatant as the readout, as previously
reported [16]. Briefly, 160 µl cell supernatant were transferred
to a 96-well culture plate and 10 µl of 30% trichloroacetic acid
was added for 30 min at 50°C. After centrifugation, 100 µl
supernatant was mixed with 100 µl freshly prepared Ehrlich's
solution and the absorbance was read with a microplate
reader at 450 nm.
Isolation of total RNA and cDNA hybridization
Total RNAs of adherent cells (four separate samples from
healthy BM and four separate samples from healthy synovium
between passage 4 and passage 6) were extracted using the
RNeasy mini kit (Qiagen S.A.) according to the manufacturer's
instructions. Radiolabeled cDNA was prepared from each
RNA sample with the Atlas array kit (Clontech, Saint QuentinArthritis Research & Therapy    Vol 7 No 6    Djouad et al.
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en Yvelines, France) by a reverse-transcription step in the
presence of α-[32P]dATP. The radiolabeled samples were
hybridized to the Human Cytokine/Receptor Atlas Nylon
cDNA Expression Array (BD Biosciences). After stringent
washes, membranes were scanned using a Phosphoimager
(Amersham Pharmacia Biotech, Saclay, France).
Gene array analysis
Quantification was performed using the AtlasImage software
(BD Biosciences). Data from each array were normalized by
the median value to eliminate the variability due to the sample
labeling or the exposure duration. The normalized median was
arbitrarily given the value 150. Analysis was performed using
the Cluster and TreeView hierarchical clustering software
developed by Eisen and colleagues [17]. Two filters have been
used: one filter aimed at retaining only genes expressed above
the median value, and the second filter retained genes for
which the difference between the maximum and minimum val-
ues was twice the median value. Data were log-transformed
(log-base 2), and the genes were median centered and clus-
tered by correlation average linkage clustering. The hierarchi-
cal clustering was visualized with TreeView.
Activin A quantification by ELISA
Total activin A was measured by means of a highly specific
solid-phase enzyme-linked immunometric assay using rea-
gents supplied by DSL-France (Cergy-Pontoise, France). The
first antibody was an anti-βA-subunit monoclonal antibody
immobilized on microplate wells. The second antibody was a
biotinylated monoclonal antibody. In order to minimize matrix
effects, the assay procedure was adapted to the culture
medium: the assay standards were reconstituted with nonin-
cubated medium, which was also used as a diluent. The assay
had no detectable cross-reaction with inhibin A, follistatin,
activin B or inhibin B. The dilution curves of high-level samples
paralleled the standard curves. The sensitivity was <0.1 ng/ml
and the inter-assay coefficient of variation was <10%.
Statistical analysis
Statistics were performed with the Student t  test or an
unpaired Mann-Whitney test as appropriate according to data
distribution. All data were analyzed by the program Instat
(Graphpad, San Diego, CA, USA).
Results
Phenotypic characterization
Adherent cells isolated from BM or synovial tissue were first
characterized according to the expression of surface markers
known to be expressed or absent on BM-MSC. By FACS anal-
ysis, we showed that more than 99% of these cells from both
tissues were negative for the expression of CD14, CD34 and
CD45 and were positive for CD44, CD73, CD90 and CD105
(Fig. 1a). Similar results were also obtained using human pri-
mary skin fibroblasts (data not shown). The fluorescence inten-
sities for each marker were not statistically different between
Figure 1
Immunophenotype of bone marrow-derived (left) and synovium-derived  adherent cells (right) Immunophenotype of bone marrow-derived (left) and synovium-derived 
adherent cells (right). (a) Fluorescence-activated cell sorting of CD 
marker expression. Results are expressed as the mean fluorescence 
intensity ± standard error of the mean. One representative experiment 
out of six different samples of bone marrow mesenchymal stem cells 
(three normal, two osteoarthritis and one rheumatoid arthritis) and syn-
ovium mesenchymal stem cells (two rheumatoid arthritis, two osteoar-
thritis and two healthy) is shown. Control corresponds to the 
fluorescence due to the isotypic control. (b) Immunofluorescence stain-
ing on cells in a monolayer using the monoclonal antibody specific for 
human prolyl-4-hydroxylase.Available online http://arthritis-research.com/content/7/6/R1304
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the two cell populations, suggesting a similar level of expres-
sion on both cell populations – except for the marker CD90 (P
= 0.0311), which was higher on MSC from synovium.
Because contradictory results were reported using the anti-
body specific for prolyl-4-hydroxylase to immunophenotype
the MSC [18,19], we checked whether it could be useful to
discriminate between MSC derived from BM or MSC derived
from synovium. Although no expression was found on both cell
populations by FACS analysis (data not shown), they were
both positive in immunocytochemistry (Fig. 1b). Similarly, the
skin fibroblast cells used as the control were also positive for
this marker (data not shown). Indeed, using various markers,
adherent cell populations isolated from the two tissues dis-
played a similar phenotype, commonly observed with MSC-
containing cell populations derived from BM.
Expression of MHC class I and class II
BM-MSC are known to be positive for MHC class I molecules
and to be negative for MHC class II molecules in basal culture
conditions, both being upregulated following treatment with
IFN-γ [1]. We confirmed these observations with the cells iso-
lated from BM used in this study (Fig. 2a) and with the syn-
ovium-derived cells (data not shown) as already reported [20].
However, no data are available on the effect of IFN-α and IFN-
β on the expression of MHC molecules on synoviocytes or
BM-MSC. We showed that, similarly to IFN-γ, IFN-α and IFN-
β significantly upregulated the MHC class I molecules in both
cell populations. Only IFN-γ significantly induced the expres-
sion of class II molecules, and both the number of positive
cells (56 ± 16% and 36 ± 17% for BM-derived and synovium-
derived cells, respectively) and their mean fluorescence were
increased (Fig. 2b). However, no statistically significant differ-
ence between cells isolated from the two tissues was
observed.
We then investigated whether the 6–16 gene, which is a rep-
resentative of the early type I IFN-stimulated genes, was also
upregulated in adherent cells isolated from BM or synovium.
The expression of the 6–16 gene was upregulated with IFN-α
and IFN-β (Fig. 2c), and to a lesser extent with IFN-γ (data not
shown), and a statistically reduced expression level was
observed with cells isolated from the synovial membrane.
Thus, for most of the markers examined, no significant differ-
ence between adherent cells from BM and synovium was
observed in our culture conditions.
Differentiation capacities
Similarly to BM-MSC, synovial-derived MSC have been
reported to differentiate into chondrocytes, osteocytes and
adipocytes [7]. We compared the expression levels of specific
markers following the induction of chondrogenesis or osteo-
genesis in vitro to accurately quantify the differentiation capac-
ities of adherent cells obtained from the two tissues. The
expression of two chondrogenic markers (collagen type II and
aggrecan) and two osteogenic markers, (osteocalcin and
alkaline phosphatase) was quantified relative to GAPDH by
quantitative RT-PCR (Fig. 3a, b). A significant increase of the
mRNA was observed on both cell populations and for all the
differentiation markers tested. The mean increase of collagen
type II and aggrecan was stronger in synovium-derived cells
than in BM-derived cells but the differences were not signifi-
cant. Notably, the collagen type II marker was induced in all
cell samples isolated from BM whereas only five out of eight
samples from the synovial tissue were positive after differenti-
ation (data not shown). Inversely, the mean induction of oste-
ocalcin and alkaline phosphatase was statistically higher in
cells from BM than in cells from the synovium. In these condi-
tions, the primary skin fibroblastic cells were unable to differ-
entiate along the chondrogenic and osteogenic pathways
(data not shown). Although a high heterogeneity in the induc-
tion of the various markers was observed between the sam-
ples, synovial cells displayed a reduced osteogenic capacity.
Immunosuppressive nature
We and others have previously shown that BM-MSC exhibit
immunosuppressive properties able to inhibit the proliferation
of T cells in a MLR [15,21]. However, nothing was known on
the behavior of synoviocytes. Similarly to BM-MSC, we
showed that MSC from the synovium were able to suppress
the proliferative capacities of T cells in a MLR whereas primary
skin fibroblasts display no suppressive properties (Fig. 4a). It
has very recently been reported that this effect may be medi-
ated by the induction of the IDO activity in BM-MSC [22]. We
thus determined whether cells derived from the synovium or
from BM may display a similar induction of IDO activity upon
IFN activation. As shown in Fig. 4b, incubation of cells with
IFN-γ but not with TNF-α resulted in a similar induction of IDO
activity in the two cell populations.
Identification of genes differentially expressed
We then compared the cDNA expression profiles of these cell
populations using the Atlas Human Cytokine/Receptor Array
membrane. Radiolabeled cDNAs of four BM-derived cells ver-
sus four synovium-derived cells from healthy donors were
hybridized on the membranes, which are composed of cDNAs
from 268 genes (Fig. 5a, b). Data were analyzed using the
Cluster and TreeView hierarchical clustering software, result-
ing in a color-coded gene expression representation: expres-
sion below the median is green, expression above the median
is red, whereas the median expression across all samples is
black. The software groups genes by similarities in their pat-
tern of expression, and groups samples by similarities in their
pattern of expression over all samples (Fig. 5c).
The analysis of the 268 genes thus ended with the classifica-
tion of samples into two groups differentiating between the
two tissue origins, BM or synovial tissue, suggesting that the
differential expression of some genes should permit one to dis-
criminate between the two cell populations (Table 1). The dif-
ferent gene expression patterns allowed us to focus on genesArthritis Research & Therapy    Vol 7 No 6    Djouad et al.
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grouped in clusters whose expression was higher in either
group. Among the genes that were overexpressed in cells iso-
lated from BM, we checked for the expression of the βA sub-
unit of inhibin or activin. The βA chains either homodimerize by
disulfide bonding to form activin A or heterodimerize with
inhibin α-chains to form inhibin A [23]. We thus used a spe-
cific ELISA developed to quantify the protein levels expressed
by adherent cells isolated from the two tissues. Indeed, we
specifically detected high levels of activin A in the
supernatants from BM-derived cells and detected lower
amounts from cells cultured from the synovial membrane (<1/
10) (Fig. 5d).
Discussion
It is now established that MSC can be isolated from the syno-
vial membrane [7] as well as from BM or other tissues (for a
review, see [1]). The culture conditions, based in part on
adherence to plastic, used to isolate MSC from the synovial
membrane are similar to those used to obtain fibroblastic syn-
oviocytes, suggesting that only a subset of cells in this syn-
ovium-derived cell population are stem cells, like MSC from
BM-derived cultures. As no specific marker for MSC is pres-
ently available, their characterization relies essentially on their
functional properties, but to date no quantitative data allow
comparison between MSC isolated from various tissues. In the
present study we have shown that BM-derived and synovium-
derived adherent cell populations can be induced to differen-
tiate towards chondrocytes and osteoblasts, but a significant
fivefold to 10-fold reduction in the expression levels of the
osteogenic markers was observed with the adherent cells
from the synovium. Furthermore, we show that the transcrip-
tional profiles permit one to discriminate between the cell pop-
Figure 2
Induction of HLA class I and class II expression by IFN in adherent cells Induction of HLA class I and class II expression by IFN in adherent cells. (a) One example of basal and IFN-γ-induced expression of HLA-A, HLA-B, 
HLA-C (left) and HLA-DR (right) molecules on mesenchymal stem cells from bone marrow (BM) by fluorescence-activated cell sorting analysis. (b) 
Expression of HLA-A, HLA-B, HLA-C (left) and HLA-DR (right) molecules by BM-derived cells (n = 5; two normal, two osteoarthritis and one rheuma-
toid arthritis) and synovium-derived cells (n = 7; three rheumatoid arthritis, two normal, two osteoarthritis) after induction with 1,000 U/ml IFN-α, IFN-
β and IFN-γ, shown as the fold increase of the mean fluorescence intensity over the control ± standard error of the mean. (c) Detection of the 6–16 
early response gene to IFN, assessed by quantitative RT-PCR, normalized to GAPDH mRNA (n = 3 for synovium-derived and n = 4 for BM-derived 
cell samples). Results display the fold increase of the 6–16 gene in IFN-induced samples over nontreated samples. * P < 0.05.Available online http://arthritis-research.com/content/7/6/R1304
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ulations isolated from BM or the synovium, and that activin A
might be a useful marker since it is highly secreted by MSC
from BM.
In agreement with other studies [8,11], we confirm that,
together with skin fibroblasts, synovium-derived adherent cells
express various markers known to be present on BM-MSC,
such as CD44, CD90 and CD105. We now show that the
cells isolated from the synovial membrane also express the
CD73 marker, an ecto-5'-nucleotidase recognized by the SH3
antibody, and express prolyl-4-hydroxylase. Prolyl-4-hydroxy-
lase was shown to be expressed by synoviocytes [18,24] but
to be absent on BM-MSC using FACS analysis [18]. In the
present study we were able to detect the protein in both cell
populations by immunocytochemistry, whereas it was negative
by FACS analysis, suggesting that this marker was not spe-
cific for synoviocytes. Expression of MHC class I molecules on
BM-MSC and synovial fibroblasts has been reported, as well
as the induction of MHC class II molecules upon treatment
with IFN-γ [25,26]. However, although IFN-β has been shown
to induce the expression of MHC class I and class II molecules
on various cell types [27,28], no data were available on the
potential role of IFN-α and IFN-β on synovial fibroblasts or BM-
MSC. To our knowledge, this is the first report to show that
IFN-α and IFN-β upregulate the MHC class I molecules and
the 6–16 gene, which is one of the early responsive genes
induced by IFN, but fail to induce the MHC class II molecules
Figure 3
In-vitro-induced differentiation of bone marrow-derived and synovium- derived adherent cells In-vitro-induced differentiation of bone marrow-derived and synovium-
derived adherent cells. (a) Chondrogenic differentiation was evaluated 
after 21 days in micropellet culture. Expression of the specific markers 
for chondrogenesis (collagen type II [Col2] and aggrecan [Agg]) was 
determined by quantitative RT-PCR from the various samples: eight 
bone marrow (BM) mesenchymal stem cells (MSC) (four healthy, two 
osteoarthritis [OA], two rheumatoid arthritis [RA]) and eight synovium-
MSC (four RA, two OA, two RA). (b) Osteogenic differentiation was 
evaluated after 21 days in monolayers. Expression of the osteogenic 
markers (osteocalcin [OC] and alkaline phosphatase [AP]) was deter-
mined by quantitative RT-PCR from the various samples: eight BM-
MSC (four healthy, two OA, two RA) and eight synovium-MSC (four 
RA, two OA, two healthy). The expression levels were normalized on the 
basis of GAPDH expression, and the results are reported as ratios of 
the marker gene versus GAPDH using the formulae 2-∆Ct (×100) ± 
standard error of the mean. Statistics compared eight cell samples from 
BM and eight cell samples from the synovium. * P < 0.05, ** P < 0.01.
Figure 4
Immunosuppressive properties of bone marrow-derived and synovium- derived adherent cells Immunosuppressive properties of bone marrow-derived and synovium-
derived adherent cells. (a) Proliferative activity of T cells in a mixed lym-
phocyte reaction. Responding BALB/c splenocytes (105 cells) were 
incubated for 4 days with mitomycin-treated DBA/1 splenocytes (105) 
in the presence or absence of 105 adherent cells from bone marrow 
(BM) (n = 10; six healthy, two rheumatoid arthritis, two osteoarthritis) or 
synovium (n = 10; five rheumatoid arthritis, two osteoarthritis, three nor-
mal) or normal fibroblasts (fibro; n = 3). The proliferative response cor-
responding to the average counts per minute of triplicates of 
alloreactive T cells (allo) was assigned the value of 100% ± standard 
deviation (SD). (b) The indoleamine 2,3-dioxygenase (IDO) activity was 
detected as the tryptophan to kinurenin conversion measured at an 
optical density (OD) of 450 nm. Cells were cultured in the absence or 
presence of IFN-γ and/or tumor necrosis factor alpha (TNF-α) for 48 
hours and the detection of kinurenin was measured by photometry. The 
IDO activity is expressed as the mean activity from four different sam-
ples of cells from each tissue ± SD.Arthritis Research & Therapy    Vol 7 No 6    Djouad et al.
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on both cell populations. Altogether, these data illustrate the
high similarity between adherent cell populations isolated from
BM and the synovium, based on the expression of various phe-
notypic markers known to be currently tested with MSC. This
suggests that these markers correspond to molecules
expressed on cells of mesenchymal origin as they are also
detected on primary skin fibroblasts (data not shown) and
points out the lack of specific markers.
The multilineage potential of MSC from the synovium has
already been described [6,7]. These studies only described
qualitative results based on histological and immunohistologi-
cal staining or semiquantitative RT-PCR. In our study, we per-
formed quantitative RT-PCR to indicate quantitative
differences in the expression level of the markers specific for
the differentiated states. Variability in gene expression was
observed between samples, independently of gender, age or
the status of the patient (normal, OA or RA) (data not shown).
Figure 5
Analysis of genes differentially expressed by normal bone marrow-derived and synovium-derived adherent cells Analysis of genes differentially expressed by normal bone marrow-derived and synovium-derived adherent cells. Total RNAs were extracted from 
cells at passages 4–6 obtained from healthy donors and reverse-transcribed to radiolabeled cDNAs before hybridization to gene array membranes 
(Atlas Human Cytokine/Receptor Array; BD Biosciences). Each gene is represented as duplicate spots. (a) One example of a representative array 
from cells isolated from bone marrow (BM) (n = 4). The arrow represents the activin/inhibin βA subunit. (b) One example of a representative array 
from synovial cells (n = 4). The arrow represents the activin/inhibin βA subunit. (c) Hierarchical clustering analysis. The dendrogram at the top repre-
sents the relationship of the samples according to the similarity in their gene expression profile. Arrows indicate some areas of genes that permit one 
to discriminate between samples. Red, high expression, green, low expression. (d) Quantification of the secreted activin A by specific ELISA. 
Results are expressed as the mean of secretion in 24-hour and 48-hour supernatants of four cell samples ± standard error of the mean.Available online http://arthritis-research.com/content/7/6/R1304
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In previous studies, the multilineage potential of synovium-
derived MSC was reported to be independent of donor age,
passaging or cryopreservation [7]. We now report that syn-
ovium-derived cells expressed significantly lower levels of
osteogenic marker mRNA after in-vitro-induced osteogenesis,
whereas these cells tended to secrete higher amounts of
chondrogenic marker mRNA after chondrogenesis induction,
although the differences with BM-derived MSC were not sta-
tistically significant. These data may reflect a different cellular
phenotype or a different amount of MSC inside the two cell
populations. Indeed, in the cells isolated from the synovium tis-
sue we measured 1.8 ± 1.4 colony-forming units in 104 plated
cells, which is in the same range obtained with cells from BM
(estimated to be 1 in 104 or 105 mononuclear cells) [29]. Alter-
natively, they may reflect a commitment of stem cells under the
influence of the environmental parameters. The presence of
progenitors already committed to the chondrogenic lineage
may be in higher amounts in the synovial membrane, where
they contribute to the homeostasis of the cartilage tissue that
is in close contact. Conversely, the higher capacity of differen-
tiation toward osteoblasts observed with cells isolated from
BM may suggest a higher numbers of cells committed to the
osteogenic lineage inside the BM. Availability of markers
specific for the MSC or different stages of differentiation
would help to answer this question.
Table 1
Genes whose mRNA expression is differentially expressed in 
bone marrow-derived or synovium-derived cells
Gene Fold changes versus day 0
Upregulated in bone marrow-derived cells
MIP-1β 40.5
IGF2 34.3
OX40 ligand 27.5
Neuregulin 26.8
Lymphotoxin-β 13.5
Acidic fibroblast growth factor 11.4
GAPDH 11.3
Lymphotoxin-α precursor 10.0
BIGH3 9.5
TRAIL 7.2
IFN-γ receptor 7.2
G-CSF 6.9
Glia-derived neurite-promoting factor 
(GDNPF)
6.4
IFN-α/β receptor β-subunit 
precursor
6.2
Hepatocyte growth factor 6.0
RPL13A 5.9
Platelet-activating factor receptor 5.6
Keratinocyte growth factor; FGF7 4.8
Endothelin receptor type A 4.5
IGF-binding protein 2 (IGFBP2) 4.1
Inhibin bA subunit precursor; activin 
bA subunit precursor
4.1
Apoptosis-related protein TFAR15 4.0
Related to receptor tyrosine kinase 
(RYK)
3.4
VEGFR1 3.3
IGF-binding protein 3 (IGFPB3) 3.0
Insulin-like growth factor I receptor 
(IGF1R)
2.9
Downregulated in bone marrow-derived cells
MIP2-α, GRO-β -26.2
IL-8 precursor -25.3
Tumor necrosis factor-inducible 
protein TSG-6
-13.8
βNGF -11.9
Granulocyte chemotactic protein 
(GCP2)
-6.2
FLT3 ligand -5.1
Leukocyte IFN-inducible peptide -4.9
BMP-4 + BMP-2B -4.7
Activin receptor-like kinase 1 (Alk1); 
transforming growth factor beta 
superfamily receptor I (TSR1)
-4.2
Tumor necrosis factor alpha -4.0
TRAIL receptor 2; death receptor 5 -3.8
BMP3B; GDF10 -3.6
Ciliary neurotropic factor receptor 
(CNTFR)
-3.6
Tumor necrosis factor receptor 
(TNFR)
-3.3
B-cell growth factor 1 precursos 
(BCGF1)
-3.2
IL-13 precursor -3.1
Transforming growth factor beta -2.8
IL-6 -2.6
ERBB2 receptor protein-tyrosine 
kinase
-2.5
IFN regulatory factor -2.3
Upregulation or downregulation refer to the fold increase higher than 
ratio 2 in bone marrow samples (n = 4) compared with synovial 
samples (n = 4), with a Mann-Whitney significance of 0.05.
Table 1 (Continued)
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Another functional characteristic of MSC is their capacity to
inhibit the proliferation of T cells in a MLR [15]. We show here
for the first time that synovium-derived cells not only suppress
the proliferative activity of T cells, but also exhibit functional
IDO activity upon stimulation with IFN-γ to the same extent as
BM-MSC. IDO activity has recently been suggested to con-
tribute to the T-cell suppressive mechanism in human MSC.
IDO has been identified as a T-cell inhibitory effector pathway
in professional antigen-presenting cells upon induction by IFN-
γ and other proinflammatory molecules such as TNF-α. This
enzyme catalyzes the conversion from tryptophan to kynure-
nine; because tryptophan is an essential amino acid, its deple-
tion will impair protein synthesis, leading to inhibition of cell
proliferation. Depletion of tryptophan has also been shown to
lead to stabilization of IL-6 and IL-8 mRNA, resulting in
increased IL-6 and IL-8 responses that were proposed to be
implicated in enhanced inflammatory responses to bacterial
challenges after a viral infection [30]. A comparison of patients
with RA, OA, psoriatic arthritis and gout recorded the highest
levels of IL-1β, IL-6, IL-8 and IDO as well as the lowest levels
of tryptophan in RA synovial fluids, indicating stimulated cellu-
lar immune responses in RA patients [31,32]. Indeed, the pos-
sible dual activity of IDO in synoviocytes as well as in BM-MSC
still needs to be elucidated. In conditions where TNF-α and
IFN-γ are only poorly present, the IDO activity may lead to an
immunosuppressive environment inside the joint favoring the
inhibition of immune cell proliferation. In the inflammatory con-
text, where TNF-α and IFN-γ are prominent, induction of proin-
flammatory cytokines may reverse the cytokine balance,
leading to a reversion of the immunosuppressive capacity of
MSC as we previously showed in the collagen-induced arthri-
tis model of arthritis [33].
The presence of MSC in the synovial membrane addresses
the question of their origin and function within the joint. MSC
in the synovium may be recruited from the blood that enters
the synovial tissue, as they are present in normal conditions
and even in higher numbers in the case of injury [8] due to their
recruitment from the other tissues where they reside. MSC
may also come from the bone marrow, which is connected
with the intra-articular space by channels, enlarged in RA
[10,34]. The role of MSC is possibly related to their potential
to repair tissues of mesodermal origin present inside the joint
in the case of traumatic or pathologic injuries [10]. Another
postulated role for MSC is their possible involvement in the
early phases of osteoarticular diseases and, in particular, in RA
[10]. Although MSC possess immunosuppressive capacities,
we have previously shown that they are unable to display a
benefit in the collagen-induced arthritis model because they
lose this property in the presence of TNF-α [33]. Moreover, the
increase of MHC class II expression on MSC upon IFN-γ stim-
ulation may further contribute to the aggravation of the immune
response. We thus may postulate that TNF-α is the key mole-
cule at the onset of RA pathogenesis that induces or contrib-
utes to modifying the characteristics of the MSC, which then
act to favor the accumulation of immunocompetent cells into
the joint.
An important feature revealed in the present study is that cells
isolated from BM and the synovial membrane could be distin-
guished by distinct gene expression profiles. Both populations
are thus characterized by the differential expression of various
genes, in particular activin A that is upregulated in BM-MSC.
Activins and inhibins are members of the transforming growth
factor beta super-family that play roles in skeletal development
and bone morphogenesis [23]. Activin A is a multifunctional
cytokine that regulates cell growth and differentiation, whose
effects are diverse depending on the cell type. In synoviocytes,
activin A has been reported to promote proliferation, to be
induced by IL-1β and to be upregulated in OA and RA patients
[35-37]. It is still unclear, however, whether activin A acceler-
ates or inhibits RA autoimmunity and inflammation. The
secretion of activin A in BM-MSC is induced by BMP-2, at
least in vitro, and therefore has been suggested to be down-
stream BMP-2 in the differentiation program that results in
skeletal development [38]. In the bone marrow, where MSC
are under the influence of transforming growth factor beta and
BMP molecules, the upregulation of activin A may be involved
early at the beginning of the cascade of events promoting
chondrogenic/osteogenic differentiation [39]. However,
activin A has been recently shown to play a role in the mainte-
nance of the pluripotency of human embryonic stem cells [40].
The maintenance of pluripotency of embryonic stem cells
could involve Wnt signaling and could occur through a cross-
talk between the transforming growth factor beta/activin and
Wnt pathways [41]. Indeed, activin A may play a dual role
according to the environmental parameters: proliferation or
maintenance of pluripotency. The higher amounts of activin A
produced by BM-MSC together with similar numbers of col-
ony-forming units further suggest their higher multipotent
potential.
In summary, the similarity between adherent cells cultured
from BM and from synovial tissue suggests a common origin.
The few discrepancies between cells may reflect the impact of
the tissue environment on the properties of MSC. Thus, due to
pathological conditions, reduced differentiation properties and
reversion of immunosuppression of MSC have been reported.
It will be of therapeutic interest to determine whether MSC
originating from various tissue sources share the same fea-
tures. In this respect, the demonstration that high levels of
activin A are produced by BM-MSC may potentially be of rele-
vance in arthritis and repair since it may be associated with the
pluripotency of the cells. MSC isolated from various tissues
not involved in the specific pathology may be an alternative
and more suitable source of cells with fully functional features
for tissue engineering.
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